Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

On August 19 2022, Immuron announced a strategic pivot, deprioritising its SARS‑CoV‑2 research—despite earlier in vitro findings suggesting antiviral potential for IMM‑124E—to refocus on the clinical development of its more advanced-stage therapeutic drug candidates. The decision came alongside the appointment of a new CEO charged with reassessing the company's product portfolio, competitive positioning, and growth drivers amid a rapidly evolving COVID-19 landscape and uncertain clinical trial feasibility due to ongoing viral evolution.

The Market Online: Immuron (ASX:IMC) shifts focus to therapeutic drug candidate